These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7200970)

  • 1. Depressed pulmonary removal of [3H]prostaglandin E1 after prolonged cardiopulmonary bypass.
    Pitt BR; Hammond GL; Gillis CN
    J Appl Physiol Respir Environ Exerc Physiol; 1982 Apr; 52(4):887-92. PubMed ID: 7200970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced impairment of pulmonary [3H]prostaglandin E1 removal in vivo.
    Pitt BR; Forder JR; Gillis CN
    J Pharmacol Exp Ther; 1983 Nov; 227(2):531-7. PubMed ID: 6195329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the lung on arterial levels of endogenous prostaglandins E and F.
    Pitt BR; Gillis CN; Hammond GL
    J Appl Physiol Respir Environ Exerc Physiol; 1981 Jun; 50(6):1161-7. PubMed ID: 7263376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depressed prostaglandin E1 and 5-hydroxytryptamine removal in patients with adult respiratory distress syndrome.
    Gillis CN; Pitt BR; Wiedemann HP; Hammond GL
    Am Rev Respir Dis; 1986 Oct; 134(4):739-44. PubMed ID: 3532886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects and arterial concentration of prostaglandin E1 during cardiopulmonary bypass.
    Okuda M; Faruhashi K; Konishi K; Muneyuki M
    Eur J Anaesthesiol; 1991 Mar; 8(2):129-34. PubMed ID: 1874208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of prostaglandin E1 in patients undergoing clinical cardiopulmonary bypass.
    van den Dungen JJ; Karliczek GF; Brenken U; van der Heide JN; Wildevuur CR
    Ann Thorac Surg; 1983 Apr; 35(4):406-14. PubMed ID: 6682305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fate of prostaglandins E(1) and A(1) in the human pulmonary circulation.
    Hammond GL; Cronau LH; Whittaker D; Gillis CN
    Surgery; 1977 Jun; 81(6):716-22. PubMed ID: 871015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic effects of prostaglandin E1 during cardiopulmonary bypass in infants and children.
    Kawamura M; Minamikawa O; Yokochi H; Maki S; Yasuda T; Mizukawa Y
    Jpn J Surg; 1982; 12(1):19-25. PubMed ID: 7200161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic side effects of prostaglandin E1 in patients before and during cardiopulmonary bypass.
    Karliczek G; van den Dungen JJ; Brenken U; Eijsman L; Kootstra GJ; Homan van der Heide JN; Wildevuur CR
    Thorac Cardiovasc Surg; 1981 Feb; 29(1):55-9. PubMed ID: 6164120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of [2-14C]prostaglandin E1 on passage through the pulmonary circulation.
    Dawson CA; Cozzini BO; Lonigro AJ
    Can J Physiol Pharmacol; 1975 Aug; 53(4):610-5. PubMed ID: 1100206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of prostaglandin E1 infusion during cardiopulmonary bypass].
    Okuda M; Ohi Y; Utsunomiya H; Kurata M; Konishi K; Muneyuki M
    Masui; 1989 Aug; 38(8):1036-41. PubMed ID: 2810697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depression of pulmonary metabolic function by cardiopulmonary bypass procedures increases levels of circulating norepinephrine.
    Pitt BR; Gillis CN; Hammond GL
    Ann Thorac Surg; 1984 Nov; 38(5):508-13. PubMed ID: 6497479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemolysis and red cell deformability during cardiopulmonary bypass--the effect of prostaglandin E1 for prevention of hemolysis].
    Yamaguchi H; Shimizu T; Akutsu H; Kawachi K; Osada K; Fujikawa T; Suesada H; Hirayama T; Ishimaru S; Furukawa K
    Nihon Kyobu Geka Gakkai Zasshi; 1990 Apr; 38(4):625-9. PubMed ID: 2373896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further identification of PGE1 metabolites formed in the cat lung.
    Cozzini BO; Dawson CA
    Can J Physiol Pharmacol; 1977 Apr; 55(2):311-3. PubMed ID: 871963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The renal function protection of prostaglandin E1 from hemolysis caused by cardiopulmonary bypass].
    Yang G; Xiao D; Wang J
    Zhonghua Yi Xue Za Zhi; 1997 Sep; 77(9):695-7. PubMed ID: 9772542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of plasma protein on the inhibitory effects of indocyanine green and bromcresol green on pulmonary prostaglandin E1 extraction.
    Dawson CA; Linehan JH; Rickaby DA; Roerig DL
    Br J Pharmacol; 1984 Mar; 81(3):449-55. PubMed ID: 6538103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective effect of microembolization on pulmonary removal of biogenic amines.
    Flink JR; Pitt BR; Hammond GL; Gillis CN
    J Appl Physiol Respir Environ Exerc Physiol; 1982 Feb; 52(2):421-7. PubMed ID: 7061295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effects of prostaglandin E1 on systemic and cerebral oxygenation before and during cardiopulmonary bypass].
    Kawahara F; Kadoi Y
    Masui; 2002 Feb; 51(2):128-33. PubMed ID: 11889777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiopulmonary actions of prostaglandin 6-keto-E1 in the anesthetized dog.
    Nandiwada P; Hyman AL; Feigen LP; Kadowitz PJ
    Arch Int Pharmacodyn Ther; 1980 May; 245(1):118-28. PubMed ID: 7190813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo disposition of prostaglandin E1 via pharmacokinetic characterization of its pulmonary metabolite.
    Verburg M; Bothwell W; Daniels EG; Fitzpatrick FA
    J Cardiovasc Pharmacol; 1982; 4(6):980-5. PubMed ID: 6185792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.